Allergen immunotherapy: Immunomodulatory treatment for allergic diseases

Expert Review of Clinical Immunology

Volumn 2, Issue 4, 2006, Pages 533-546

  Cox, Linda ^a  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALLERGEN; ALUTARD SQ; ANTIGEN; BRONCHODILATING AGENT; CAN F 1; CORTICOSTEROID; FEL D; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN G4; INTERLEUKIN 10; OMALIZUMAB; PARIETARIA JUDAICA ANTIGEN; PHLEUM PRATENSE ANTIGEN; RAGWEED ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VENOM;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; APPLICATION SITE REACTION; ASTHMA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HAY FEVER; HUMAN; HYPERSENSITIVITY; HYPOTENSION; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MAINTENANCE DRUG DOSE; META ANALYSIS; OPTIMAL DRUG DOSE; PARIETARIA; PARIETARIA JUDAICA; PATIENT SELECTION; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; T LYMPHOCYTE; TH2 CELL; TIME; TREATMENT INDICATION;

EID: 33748486704     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.4.533     Document Type: Review

References (89)

1. Simons Estelle F. Ancestors of Allergy. New York Global Medical Communications Ltd, NY, USA (1994).
2. Freeman J. Further observations of the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 814-817 (1911).
3. Freeman J. 'Rush inoculation', with special reference to hay fever treatment. Lancet 744-747 (1930).
4. Noon L. Prophylactic inoculation against hay fever. Lancet 1572-1573 (1911).
5. Ishzaka K, Ishizaka T. Identification of gamma-E antibodies as a carrier of reaginic activity. J. Immunol. 99, 1187-1199 (1967).
6. Durham SR, Varney VA, Gaga M et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin. Exp. Allergy 29(11), 1490-1496 (1999).
7. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61(2), 151-165 (2006).
8. Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin. Exp. Allergy 23(8), 647-660 (1993).
9. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin. Allergy 17(5), 459-468 (1987).
10. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113(6), 1025-1034 (2004).
11. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J. Allergy Clin. Immunol. 112(5), 915-922 (2003).
12. Shamji MH, Larche M, Francis JN, Durham SR. Validation of a functional assay of IgE-facilitated CD23-dependent allergen binding to B cells to monitor clinical efficacy of immunotherapy (abstract). J. Allergy Clin. Immunol. 117(2), S330 (2006).
13. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β the role of T regulatory cells. Immunology 117(4), 433-442 (2006).
14. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy, J. Allergy Clin. Immunol. 111(6), 1255-1261 (2003).
15. Wilcock LK, Paraskavopoulos G, Till SJ, Durham SR. Induction of IL-10 occurs early and precedes serum IgG blocking activity during a cluster regimen of grass pollen immunotherapy (abstract). J. Allergy Clin. Immunol. 117(2), 330 (2006).
16. Michils A, Baldassarre S, Ledent C, Mairesse M, Gossart B, Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy 55(5), 455-462 (2000).
17. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin. Exp. Allergy 36(4), 465-474 (2006).
18. Ross RN, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis. Clin. Ther. 22, 342-350 (2000).
19. Ross RN, Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin. Ther. 22, 351-358 (2000).
20. Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61(2), 202-205 (2006).
21. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am. J. Respir. Crit. Care Med. 151, 969-974 (1995).
22. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin. Ther. 22, 329-341 (2000).
23. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 4, CD001186 (2003).
24. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J. Allergy Clin. Immunol. 113(4), 643-649 (2004).
25. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108(Suppl. 5), S147-S334 (2001).
26. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 61(2), 198-201 (2006).
27. Guilbert TW, Morgan WJ, Zeiger RS et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N. Engl. J. Med. 354(19), 1985-1997 (2006).
28. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N. Engl. J. Med. 343(15), 1054-1063 (2000).
29. Lent AM HR, Sills M, Schmidt K, Efaw B, Lebo TS. Immunological response to administration of standardized dog allergen extract at differing doses (abstract). J. Allergy Clin. Immunol. 117(2), S330 (2006).
30. Nanda A, O'Connor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J. Allergy Clin. Immunol. 114(6), 1339-1344 (2004).
31. Ewbank P, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind placebo-controlled immunotherapy dose-response study with standardized cat extract. J. Allergy Clin. Immunol. 111, 155-161 (2003).
32. Creticos P, Adkinson NF Jr, Kagey-Sobotka A et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J. Clin. Invest. 76, 2247-2253 (1985).
33. Bosquet J, Soussana M, Michel F-B. Double-blind placebo-controlled immunotherapy grass-pollen allergoids IV. Compaarison of the safety and efficacy of two doses of a high-molecular-weight allergoid. Immunotherapy. J. Allergy Clin. Immunol. 85(2), 490-497 (1990).
34. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 319-325 (2006).
35. Haugaard L, Dahl RJ, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J. Allergy Clin. Immunol. 91, 709-722 (1993).
36. Kohno Y, Minoguchi K, Oda N et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J. Allergy Clin. Immunol. 102(6 Pt 1), 927-934 (1998).
37. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341(7), 468-475 (1999).
38. Des Roches A, Paradis L, Knani J et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 51(6), 430-433 (1996).
39. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109(2), 251-256 (2002).
40. Valovirta E, Niggemann B, Dreborg S et al. A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study. J. Allergy Clin. Immunol. 117(3) (2006) (Abstract).
41. Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir. Res. 6, 153 (2005).
42. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 114(4), 851-857 (2004).
43. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 99(4), 450-453 (1997).
44. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31(9), 1392-1397 (2001).
45. Purello-D'Ambrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy 31(8), 1295-1302 (2001).
46. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 59(11), 1205-1210 (2004).
47. Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann. Allergy 73(5), 409-418 (1994).
48. Tabar AI, Echechipia S, Garcia BE et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J. Allergy Clin. Immunol. 116(1), 109-118 (2005).
49. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 97(6), 1207-1213 (1996).
50. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J. Allergy Clin. Immunol. 106(5), 840-843 (2000).
51. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann. Allergy Asthma Immunol. 92(2), 225-227 (2004).
52. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. 87(1 Suppl. 1), 47-55 (2001).
53. Parmiani S, Fernandez Tavora L, Moreno C, Guardia P, Rico P. Clustered schedules in allergen-specific immunotherapy. Allergol. Immunopathol. (Madr.) 30(5), 283-291 (2002).
54. Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann. Allergy Asthma Immunol. 76(2), 175-180 (1996).
55. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J. Allergy Clin. Immunol. 117(1), 169-175 (2006).
56. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 113(6), 1129-1136 (2004).
57. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J. Allergy Clin. Immunol. 92(1 Pt 1), 6-15 (1993).
58. Lockey RF. Adverse reactions associated with skin testing and immunotherapy. Allergy Proc. 16(6), 293-296 (1995).
59. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Allerg. Immunol. (Paris) 36(2), 52-55 (2004).
60. Casale TB, Busse WW, Kline JN et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 117(1), 134-140 (2006).
61. Bagnasco M, Mariani G, Passalacqua G et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J. Allergy Clin. Immunol. 100(1), 122-129 (1997).
62. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 117(5), 1021-1035 (2006).
63. Ciprandi G, Fenoglio D, Cirillo I et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann. Allergy Asthma Immunol. 95(1), 38-44 (2005).
64. Ciprandi G, Fenoglio D, Cirillo I, Milanese M, Minuti P. Sublingual immunotherapy and regulatory T cells. Allergy 61(4), 511-513 (2006).
65. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy 35(5), 565-571 (2005).
66. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J. Investig. Allergol. Clin. Immunol. 15, 9-16 (2005).
67. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60(1), 4-12 (2005).
68. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy 33(2), 206-210 (2003).
69. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J. Allergy Clin. Immunol. 114(4), 831-837 (2004).
70. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59(1), 45-53 (2004).
71. Andre C, Perrin-Fayolle M, Grosclaude M et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int. Arch. Allergy Immunol. 131(2), 111-118 (2003).
72. Ali FR, Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev. Vaccines 4(6), 881-889 (2005).
73. Schramm G, Kahlert H, Suck R et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 56 with reduced IgE-binding capacity but conserved T cell reactivity. J. Immunol. 162(4), 2406-2414 (1999).
74. Smith AM, Chapman MD, Taketomi EA, Platts-Mills TA, Sung SS. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J. Allergy Clin. Immunol. 101(3), 423-425 (1998).
75. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60(10), 1269-1274 (2005).
76. Alexander C, Ying S, B Kay A, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy 35(1), 52-58 (2005).
77. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet 360, 47-53 (2002).
78. Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol. 111(4), 854-861 (2003).
79. Muller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101(6 Pt 1), 747-754 (1998).
80. Immonen A, Farci S, Taivainen A et al. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J. Immunol. 175(6), 3614-3620 (2005).
81. Kwon SS, Kim NS, Yoo TJ. Vaccination with DNA encoding human T-cell epitopes suppresses Der p induced allergic responses in mice. J. Asthma 42(2), 119-125 (2005).
82. Chapman MD, Smith AM, Vailes LD, Arruda LK, Dhanaraj V, Pomes A. Recombinant allergens for diagnosis and therapy of allergic disease. J. Allergy Clin. Immunol. 106(3), 409-418 (2000).
83. Bohle B, Breitwieser A, Zwolfer B et al A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol. 172 (11), 6642-6648 (2004).
84. Nopp A, Hallden G, Lundahl J et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J. Allergy Clin. Immunol. 106(1 Pt 1), 101-109 (2000).
85. Jain VV, Kitagaki K, Kline JN. CpG DNA and immunotherapy of allergic airway diseases. Clin. Exp. Allergy 33(10), 1330-1335 (2003).
86. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113(6), 1144-1151 (2004).
87. Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113(2), 235-241 (2004).
88. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 90(1 Suppl. 1), 1-40 (2003).
89. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29. Allergy 53(44 Suppl.), 1-42 (1997).